Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
Autore:
Rascol, O; Arnulf, I; Paul, HPS; Brefel-Courbon, C; Vidailhet, M; Thalamas, C; Bonnet, AM; Descombes, S; Bejjani, B; Fabre, N; Montastruc, JL; Agid, Y;
Indirizzi:
Univ Hosp, Dept Clin Pharmacol, Clin Invest Ctr, Toulouse, France Univ Hosp Toulouse France Pharmacol, Clin Invest Ctr, Toulouse, France Univ Hosp, INSERM, U455, Toulouse, France Univ Hosp Toulouse FranceUniv Hosp, INSERM, U455, Toulouse, France Univ Paris, Hop La Pitie Salpetriere, Dept Neurol, Clin Invest Ctr, F-75252 Paris, France Univ Paris Paris France F-75252 , Clin Invest Ctr, F-75252 Paris, France Univ Paris, Hop La Pitie Salpetriere, INSERM, U289, F-75252 Paris, France Univ Paris Paris France F-75252 ere, INSERM, U289, F-75252 Paris, France Inst Rech Pierre Fabre, Boulogne, France Inst Rech Pierre Fabre BoulogneFrance h Pierre Fabre, Boulogne, France
Titolo Testata:
MOVEMENT DISORDERS
fascicolo: 4, volume: 16, anno: 2001,
pagine: 708 - 713
SICI:
0885-3185(200107)16:4<708:IAAAAL>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEVODOPA-INDUCED DYSKINESIAS; MPTP; YOHIMBINE; RATS; NORADRENALINE; RECEPTORS; AGONISTS; BEHAVIOR; MONKEYS; CORTEX;
Keywords:
idazoxan; alpha 2 receptors; Parkinson's disease; L-DOPA, dyskinesia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Rascol, O Fac Med Toulouse, Lab Pharmacol Med & Clin, 37 Allees Jules Guesde, F-31073 Toulouse, France Fac Med Toulouse 37 Allees Jules Guesde Toulouse France F-31073
Citazione:
O. Rascol et al., "Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease", MOVEMENT D, 16(4), 2001, pp. 708-713

Abstract

Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effectsof single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dyskinetic patients with Parkinson's disease. (C) 2001 Movement Disorder Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 15:47:17